-

TIME Selects Viz.ai CEO Dr. Chris Mansi in TIME100 AI List of the World's Most Influential People in Artificial Intelligence

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, is pleased to announce that its CEO and co-founder, Dr. Chris Mansi, has been named an Innovator on the prestigious 2024 TIME100 AI list, an honor that recognizes the world’s 100 most influential people advancing and shaping artificial intelligence (AI).

“It is an incredible honor to be included on the TIME100 AI list alongside such diverse and future-driven thinkers, but it is also a reflection of the collective efforts of our team at Viz.ai,” said Dr. Chris Mansi. “Since we started Viz.ai, we’ve been dedicated to advancing healthcare systems to work smarter and faster, and ultimately improve patient outcomes through artificial intelligence. We will continue to revolutionize the way patient care is delivered.”

As a trained neurosurgeon, Dr. Mansi is familiar with the challenges patients face in accessing treatments when they are needed. Inspired by a patient who underwent a successful brain surgery and yet died because the surgery came too late, Dr. Mansi founded Viz.ai in 2016 with a goal of using artificial intelligence to accelerate care coordination and reduce systemic delays that stand between patients and life-saving treatments.

“Chris's unwavering commitment to increasing patient access to life-saving treatments is deserving of this recognition,” said Mamoon Hamid, Partner, Kleiner Perkins. “The significance of the Viz.ai team's impact cannot be overstated. They are getting patients to the right diagnosis, specialist, and treatment faster, ensuring that they don’t get lost in our complex healthcare system.”

With two de Novo clearances by the Food and Drug Administration (FDA) since 2018 and more than 50,000 providers today across 1700 hospitals on the end-to-end platform, Viz.ai continues to lead transformation in healthcare and life sciences and provide real-world impacts for patients.

The TIME100 AI list is an annual global recognition that features remarkable leaders, scientists, policymakers, and entrepreneurs across various fields who are shaping today's AI landscape. To assemble the list, TIME's editors and reporters solicited nominations and recommendations from industry leaders and dozens of expert sources. The TIME100 AI list will be featured in the September 16, 2024 issue of TIME, available on newsstands beginning Friday, September 6.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700 hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai OneTM is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Media Contact
Brendi Bluitt
brendi.bluitt@finnpartners.com

Viz.ai, Inc.


Release Versions

Contacts

Media Contact
Brendi Bluitt
brendi.bluitt@finnpartners.com

Social Media Profiles
More News From Viz.ai, Inc.

A Decade of Increasing Access to Life Saving Treatments: Viz.ai Celebrates 10 Years, 2,000 Hospitals, and 230 Million Patients

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today celebrates its 10th anniversary, marking a decade of transforming how healthcare teams deliver care for patients. The company launched in 2016 to solve a key problem: variability in healthcare means that many patients fail to get guideline based care, even in life threatening diseases like stroke. Since achieving the first FDA clearance for an AI platform and increasing tr...

Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to pote...

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growi...
Back to Newsroom